Fabrication and Characterization of Medical Mesh-Nebulizer for Aerosol Drug Delivery

Choi, Kee-Bong; Moon, Sang-Hyub; Park, Su-Kang; Cho, Guangsup; Nam, Ki Chang; Park, Bong Joo

doi:10.3390/app8040604

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that lung deposition was significantly higher for the investigational vibrating mesh nebulizers in an in vitro model of a preterm infant of 32-weeks gestational age. Recently, Choi et al [20] manufactured a micro-porous mesh nebulizer with an optimized Pd-Ni membrane filter. Their results showed a good biocompatibility and an excellent durability which makes this nebulizer quite promising for its use in biomedical engineering.…”

Section: Introductionmentioning

confidence: 99%

Experimental Evaluation of Perfluorocarbon Aerosol Generation with Two Novel Nebulizer Prototypes

et al. 2019

View full text Add to dashboard Cite

The potential of non-invasive ventilation procedures and new minimally invasive techniques has resulted in the research of alternative approaches as the aerosolization for the treatment of respiratory distress syndrome (RDS). The aim of this work was to design two nebulizer prototypes and to evaluate them studying the particle size distribution of the inhaled droplets generated with distilled water and two perfluorocarbons (PFCs). Different experiments were performed with driving pressures of 1–3 bar for each compound. An Aerodynamic Particle Sizer was used to measure the aerodynamic diameter (Da), the mass median aerodynamic diameter (MMAD) and the geometric standard deviation (GSD). The results showed that both prototypes produced heterodisperse aerosols with Da mean values in all cases below 5 µm. The initial experiments with distilled water showed MMAD values lower than 9 µm and up to 15 µm with prototype 1 and prototype 2, respectively. Regarding the PFCs, relatively uniform MMAD values close to 12 µm were achieved. The air delivery with outer lumens of prototype 1 presented more suitable mass distribution for the generation and delivery of a uniform aerosol than the two half-circular ring geometry proposed in the prototype 2.

show abstract

Section: Introductionmentioning

confidence: 99%

Experimental Evaluation of Perfluorocarbon Aerosol Generation with Two Novel Nebulizer Prototypes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This applies especially to newborns and infants. The role of mesh nebulizers, which generate homogeneous aerosol particles (monodisperse aerosol) and are characterized by low drug losses, short nebulization time and high predicted lung deposition, is becoming increasingly important [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

A comparison of the costs of bronchodilator delivery methods in children with asthma exacerbations treated in hospital. The first Polish study in children

Janeczek¹,

Bodajko-Grochowska²,

Emeryk³

et al. 2021

pdia

View full text Add to dashboard Cite

Introduction: Recommended methods of administering bronchodilator drugs in children with asthma exacerbations in a hospital include the pressurized metered-dose inhaler (pMDI) and nebulization (NEB). These methods differ in clinical effectiveness, safety and, as some studies indicate, the cost of their use in a child. Aim: To calculate the direct costs of hospital therapy conducted with the use of short-acting β 2-agonist (SABA) or its combination with short-acting muscarinic antagonist (SAMA) administered via pMDI with valved holding chamber (VHC) versus the same drugs in NEB in children with asthma exacerbation. Material and methods: A retrospective analysis of the costs of SABA (salbutamol) and SABA + SAMA (fenoterol + ipratropium bromide) inhalation therapy was performed. Based on the data obtained from the financial department, the pharmacy, and the sterilization department of the university hospital, the direct unit cost of the inhalation therapy in the child was calculated. Results: The results of the analysis indicate that in a hospital setting the cost of one-time SABA or SABA + SAMA administration via pMDI+VHC is 1.5-2.4 times lower compared to NEB. The payer incurred the lowest costs during anti-obstructive treatment using SABA with pMDI + VHC (PLN 9.39 for one inhalation procedure). The working time of medical staff during the inhalation treatment is the component generating the highest cost for the hospital (up to 40% of direct costs). Conclusions: In hospital conditions, the supply of SABA or SABA + SAMA with the use of pMDI + VHC in a child with asthma exacerbation is more beneficial financially than the supply of the same drugs in NEB.

show abstract

“…It is well known that jet nebulizers generally decrease the reservoir’s solution temperature during the first 2 min of operation, whereas ultrasonic nebulizers increase the temperature by ~20 °C within a few minutes [ 45 ]. Mesh nebulizers are based on further development of the ultrasonic nebulization principle to improve aerosol generation efficiency, speed of nebulization, and device handling, as well as to reduce residual volumes; however, optimizing protein stability during nebulization has not been not a primary concern [ 31 , 46 ]. As research began to deliver expensive proteins directly into the lungs using a nebulizer, researchers examined whether proteins were stably nebulized with various type of nebulizers, because aggregation and degradation of proteins can reduce protein activity or even result in immunogenicity [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers

et al. 2020

Self Cite

View full text Add to dashboard Cite

Recent reports on mesh nebulizers suggest the possibility of stable nebulization of various therapeutic protein drugs. In this study, the in vitro performance and drug stability of jet and mesh nebulizers were examined for dornase alfa and compared with respect to their lung delivery efficiency in BALB/c mice. We compared four nebulizers: two jet nebulizers (PARI BOY SX with red and blue nozzles), a static mesh nebulizer (NE-U150), and a vibrating mesh nebulizer (NE-SM1). The enzymatic activity of dornase alfa was assessed using a kinetic fluorometric DNase activity assay. Both jet nebulizers had large residual volumes between 24% and 27%, while the volume of the NE-SM1 nebulizer was less than 2%. Evaluation of dornase alfa aerosols produced by the four nebulizers showed no overall loss of enzymatic activity or protein content and no increase in aggregation or degradation. The amount of dornase alfa delivered to the lungs was highest for the PARI BOY SX-red jet nebulizer. This result confirmed that aerosol droplet size is an important factor in determining the efficiency of dornase alfa delivery to the lungs. Further clinical studies and analysis are required before any conclusions can be drawn regarding the clinical safety and efficacy of these nebulizers.

show abstract

Fabrication and Characterization of Medical Mesh-Nebulizer for Aerosol Drug Delivery

Cited by 14 publications

References 25 publications

Experimental Evaluation of Perfluorocarbon Aerosol Generation with Two Novel Nebulizer Prototypes

Experimental Evaluation of Perfluorocarbon Aerosol Generation with Two Novel Nebulizer Prototypes

A comparison of the costs of bronchodilator delivery methods in children with asthma exacerbations treated in hospital. The first Polish study in children

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers

Contact Info

Product

Resources

About